Having trouble viewing this email? View it as a Web page.

Patent Trial and Appeal Board

USPTO issues precedential decision detailing the principles underlying the Director’s exercise of discretion

Magnolia Medical Technologies, Inc. v. Kurin, Inc., IPR2026-00097, Paper 17 (Director May 14, 2026) (precedential)

In this decision, the Director explains that, in the Leahy-Smith America Invents Act (AIA), Congress afforded significant discretion to the Director in instituting AIA reviews, including inter partes reviews (IPRs) and post-grant reviews. In exercising that discretion, the Director considers public interest factors, including the economy, efficient administration of the Office, the ability of the Office to timely complete AIA reviews, and the integrity of the patent system.

Applying these principles, the Director denies institution of the IPR as outside the purpose of AIA reviews. The Director determines that the petitioner is not using the IPR process as an alternative to litigation and, instead, is seeking a repeat challenge after it had already litigated the same issues in the district court and lost.

Learn more about precedential and informative decisions.

 ​  ​      ​    ​ 

Having trouble accessing links in this email? Your email server security software may be altering the links. Contact your IT or email administrator and ask them to "allow-list" links-1.govdelivery.com and links-2.govdelivery.com to ensure you can access all content in this communication.

Stay connected with the USPTO by subscribing to regular email updates. Visit our subscription center at www.uspto.gov/subscribe to update or change your email preferences.

This email was sent from an unmonitored mailbox. To contact us, please visit our website www.uspto.gov/about/contacts. To ensure that you continue to receive our news and notices, please modify your email filters to allow mail from subscriptioncenter@subscriptions.uspto.gov.